Results 181 to 188 of about 22,142 (188)

Deuterated ibrutinib

2015
TUNG ROGER D, MORGAN ADAM J
openaire   +3 more sources

Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies

Journal of Thrombosis and Haemostasis, 2017
Joseph J Shatzel, Owen J T McCarty, T G Deloughery   +2 more
exaly  

Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib

Cancer, 2017
Zeev Estrov, Hagop Kantarjian, Susan O'Brien   +2 more
exaly  

Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants

Pharmacology Research and Perspectives, 2015
Jan Snoeys, Peter Hellemans, Juthamas Sukbuntherng   +2 more
exaly  

Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.

Clinical Infectious Diseases, 2018
M Lia Palomba, Susan Seo, Ying Taur
exaly  

Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” study

Hematological Oncology, 2017
Mehdi Hamadani, Oscar Calzada, Jonathon B Cohen   +2 more
exaly  

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients Free

Blood, 2013
Marcel Spaargaren, Betty Y Chang, Joseph J Buggy   +2 more
exaly  

Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

British Journal of Haematology, 2018
Shaojun Zhang, Rashmi Kanagal-shamanna, Linghua Wang   +2 more
exaly